BRAF and metastatic melanoma: In late 2014, both nivolumab and pembrolizumab received their first FDA-approved indications for use in unresectable or metastatic melanoma in patients with history of disease progression following ipilimumab and, if BRAF V600 mutation positive, BRAF inhibition.